Key facts
- This page summarizes Richard B. Lanman's Form 4 filing for BIOLASE, INC (BIOLQ).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2021, 21:04.
Richard B. Lanman - 11 Jun 2021 Form 4 Insider Report for BIOLASE, INC (BIOLQ)
- Reporting relationship
- Director
- Issuer ticker
- BIOLQ
- Reported as of
- 11 Jun 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Michael C. Carroll, attorney-in-fact for Richard B. Lanman
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Richard B. Lanman filed Form 4 for BIOLASE, INC (BIOLQ) on 14 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIOL
transaction
Derivative
Stock Appreciation Right
Award
- Transaction value
- $0
- Shares
- +104,603
- Change %
- Price
- $0.000000
- Shares after
- 104,603
- Date
- 11 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 104,603
- Exercise price
- $0.8400
- Footnotes
- F1
BIOL
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +138,000
- Change %
- Price
- $0.000000
- Shares after
- 138,000
- Date
- 11 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 138,000
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Of the stock appreciation rights subject to this SAR, one-fourth of the stock appreciation rights vest on each of the third, sixth, ninth, and twelfth-month anniversaries of the date of grant.
Footnote F2
At the option of the Company, each restricted stock unit represents the right to receive, at settlement, one share of common stock, or its cash equivalent.
Footnote F3
The restricted stock unit award fully vests and is immediately exercisable upon the filing with the SEC of the Annual Report on Form 10-K for the year ending December 31, 2023.